Al­ny­lam ex­pands RNAi com­mer­cial­iza­tion deal in Eu­rope

Al­ny­lam is dou­bling down on a part­ner­ship to ex­pand its com­mer­cial pres­ence in Eu­rope, as it forges ahead on for­mer CEO John Maraganore’s mis­sion to be­come a top-five biotech by the mid­dle of the decade.

The com­pa­ny an­nounced on Thurs­day that it’s ex­pand­ing a five-year-run­ning com­mer­cial part­ner­ship with Medi­son Phar­ma. While the duo ini­tial­ly paired up in 2019 to com­mer­cial­ize Al­ny­lam’s RNA in­ter­fer­ence port­fo­lio in Is­rael, they’re now adding Poland, the Czech Re­pub­lic, Hun­gary, Slo­va­kia, Lithua­nia, Es­to­nia and Latvia to the list.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER